Monoclonal antibodies to K5 and K5/6 have been used to identify basal-like triple negative breast cancers [17, 18] and high K5/6 expression was found to be associated with an increased risk of breast cancer relapse and death [17, 19, 20]. Here, KRT5 is linked to triple-negative breast carcinoma.